VANCOUVER, British Columbia, July 06, 2022 (World NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive distribution arrangement with SCOPE Ophthalmics. (“SCOPE”), an Irish centered eyecare firm with a emphasis on preservative free of charge therapies in ophthalmology. Beneath the distribution settlement, Aequus will get the Canadian industrial legal rights to 10 exceptional products and solutions of SCOPE’s portfolio of more than-the-counter ophthalmology products and solutions such as the OPTASE® vary of preservative totally free dry eye goods.
“We are enthusiastic to insert SCOPE’s exclusive goods and brand names to our current portfolio of large-top quality dry eye solutions. These items deliver many synergies and strengths to the two our Canadian Eye Treatment industry experts and their individuals,” reported Grant Larsen, CCO of Aequus. “We look forward to sourcing and ongoing growth of large-high-quality therapy possibilities that features devices, therapies and digital alternatives that assistance Canadian Eye Treatment Experts and their clients.” Doug Janzen, CEO and Chairman of Aequus, explained, “The addition of this portfolio of ophthalmology items will give Aequus one particular of the greatest ranges of preservative absolutely free therapies in Canada and even further demonstrates our determination to eye treatment specialists in Canada.”
“Through the signature of this collaboration with Aequus, SCOPE is growing its footprint in North The usa for Optase and our other eyecare models. Canada is clearly a nation of strategic significance for SCOPE in which our impressive eyecare items, alongside one another with the strong relationships of Aequus amongst Eye Care Professionals as nicely as its general credibility in the marketplace, will certainly contribute to the results of both of those businesses,” claimed Tom Freyne, CEO at SCOPE.
Below the proposed conditions of the agreement, SCOPE will source the items while Aequus will be accountable for Canadian authorization, advertising, distribution, and profits pursuits. SCOPE has a broad portfolio and pipeline of ophthalmology solutions that has had good results in Europe and lately introduced in the US. Aequus will have very first correct of refusal on any new items SCOPE needs to commercialize in Canada. Aequus anticipates launching decide on products in SCOPE’s portfolio afterwards this calendar year.
ABOUT AEQUUS Pharmaceuticals INC.
Aequus Prescription drugs Inc. (TSX-V: AQS, OTCQB: AQSZF) is a escalating specialty pharmaceutical firm centered on establishing and commercializing significant high quality, differentiated solutions. Aequus has grown its sales and promoting endeavours to contain many business goods in ophthalmology and transplant. Aequus designs to create on its Canadian commercial system by the start of additional products and solutions that are both created internally or brought in by means of an acquisition or license remaining concentrated on highly specialised therapeutic locations. For even further info, you should visit www.aequuspharma.ca.
ABOUT SCOPE OPHTHALMICS
SCOPE is a spouse and children have business enterprise from Ireland offering a wonderful vary of eyecare items to help deal with eye problems these as Dry Eyes, Blepharitis, Meibomian Gland Dysfunction (MGD) and Age-Similar Macular Degeneration (AMD). Launched in 2009, SCOPE is a corporation of 140 folks currently with headquarters in Dublin and immediate subsidiaries in London and New York, remember to stop by www.scopeeyecare.com.
Ahead-On the lookout Statements:
This release may perhaps include forward-wanting statements or forward-hunting info below relevant Canadian securities laws that may well not be centered on historic truth, such as, with no limitation, statements that contains the text “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and comparable expressions. Ahead- on the lookout statements are always based mostly on estimates and assumptions created by us in gentle of our practical experience and perception of historical traits, present ailments and predicted potential developments, as nicely as the things we believe are suitable. Forward-wanting statements incorporate but are not confined to statements relating to: productive launch of the SCOPE solutions, the implementation of our business design and strategic designs income advancement tendencies into the upcoming envisioned timing for product launch the Company’s predicted revenues. These kinds of statements reflect our present views with respect to potential situations and are subject to challenges and uncertainties and are essentially based on a variety of estimates and assumptions that, even though viewed as realistic by Aequus, are inherently subject matter to major enterprise, economic, aggressive, political and social uncertainties and contingencies. Lots of elements could cause our true success, performance or achievements to be materially distinctive from any long run effects, functionality, or achievements that may well be expressed or implied by these types of forward-on the lookout statements. In building the forward looking statements incorporated in this launch, the Firm has made many content assumptions, which includes, but not constrained to: obtaining regulatory approvals general organization and economic situations the Company’s skill to efficiently out license or offer its current solutions and in-license and develop new merchandise the assumption that the Company’s current great associations with 3rd parties will be taken care of the availability of funding on fair conditions the Company’s skill to attract and keep expert staff market levels of competition the goods and technological know-how made available by the Company’s competitors and the Company’s means to shield patents and proprietary legal rights. In evaluating forward hunting statements, current and potential shareholders really should especially think about various aspects established out herein and below the heading “Risk Factors” in the Company’s Annual Info Form dated June 30, 2022, a copy of which is obtainable on Aequus’ profile on the SEDAR web page at www.sedar.com, and as usually disclosed from time to time on Aequus’ SEDAR profile. Should just one or extra of these challenges or uncertainties, or a danger that is not at this time known to us materialize, or should really assumptions fundamental people forward-looking statements confirm incorrect, true success might change materially from those described herein. These forward-on the lookout statements are manufactured as of the day of this release and we do not intend, and do not believe any obligation, to update these ahead-wanting statements, except as required by applicable securities guidelines. Traders are cautioned that ahead-looking statements are not guarantees of long run performance and are inherently unsure. Appropriately, investors are cautioned not to set undue reliance on forward on the lookout statements.
Aequus Speak to Info:
Aequus Investor Relations
Electronic mail: [email protected]
Cell phone: 604-336-7906
CBJ Newsmakers
